NCT02770625View on ClinicalTrials.gov

Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

March 31, 2013

Study Completion Date

August 31, 2014

Conditions
Gaucher Disease, Type 1
Interventions
DRUG

ISU302

60 U/kg given intravenously

All Listed Sponsors
lead

ISU Abxis Co., Ltd.

INDUSTRY

NCT02770625 - Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease | Biotech Hunter | Biotech Hunter